Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy

Neuropsychopharmacology

Volumn 23, Issue 4, 2000, Pages 428-438

  Bolo, Nicolas R ^a   Hodé, Yann ^a   Nédélec, Jean François ^a   Lainé, Eric ^a   Wagner, Gabrielle ^a   MacHer, Jean Paul ^a  

^a FORENAP   (France)

Author keywords

Brain; CNS; Drug tissue distribution; Fluorine MRS; Fluoxetine; Fluvoxamine; Magnetic resonance spectroscopy; Pharmacokinetics

Indexed keywords

ANTIDEPRESSANT AGENT; FLUORINE; FLUOXETINE; FLUVOXAMINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; DEPRESSION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MENTAL DISEASE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; TISSUE DISTRIBUTION;

ADULT; AGED; BRAIN; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUORINE RADIOISOTOPES; FLUOXETINE; FLUVOXAMINE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS;

EID: 0033828077     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00116-0     Document Type: Article

References (19)

1. Altamura A.C., Moro A., Percudani M. Clinical pharmacokinetics of fluoxetine. Drug Dispo. 26(3):1994;201-214.
2. Bolo NR, Hodé Y, Macher JP (1996): Comparison of plasma and in-vivo brain levels of fluvoxamine measured by fluorine NMR spectroscopy during drug washout. In Proceedings of the International Society for Magnetic Resonance in Medicine; New York, NY, 2:1179.
3. Bolo NR, Hodé Y, Hennel F, Nédélec JJ, Lainey E, Macher JP (1997): Localization of fluvoxamine signal in-vivo by fluorine chemical shift imaging at 3T. In Proceedings of the International Society for Magnetic Resonance in Medicine. Vancouver, Canada, 2:1431.
4. Brown T.R., Kincaid B.M., Ugurbil K. NMR chemical shift imaging in three dimensions. Proc Natl Acad Sci USA. 79:1982;3523-3526.
5. De Vries M.H., Van Harten J., Van Bemmel P., Raghoebar M. Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects. Biopharm Drug Disp. 14:1993;291-296.
6. 19F nuclear magnetic resonance spectroscopy. Psychiatry Res Neuroimag. 35:1990;107-114.
7. GraphPad-Prism (1995): Graph Pad Software Inc. Version 2.00.
8. 19F -nuclear magnetic resonance spectroscopy study Psychiatry Res Neuroimag. 45(2):1992;95-104.
9. Karson C.N., Newton J.E.O., Livingston R., Jolly J.B., Cooper T.B., Komoroski R.A. Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci. 5:1993;322-329.
10. Kelly M.J., Perry P.J., Holstad S.G., Garvey M.J. Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Therap Drug Monit. 11:1989;165-170.
11. 19F spin relaxation and localized spectroscopy of fluoxetine in human brain. Magn Res Med. 31:1994;204-211.
12. 19F NMR spectroscopy. Biol Psychiatry. 29:1990;711-714.
13. Miner C.M., Davidson J.R., Potts N.L., Tupler L.A., Charles H.C., Krishnan K.R. Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia. Biol Psychiatry. 38:1995;696-698.
14. Palmer K.J., Benfield P. Fluvoxamine. An overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs. 1(1):1994;57-87.
15. Renshaw P.F., Guimares A.R., Fava M., Rosenbaum J.F., Pearlman J.D., Flood J.G., Puopolo P.R., Clancy K., Gonzalez R.G. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am J Psychiatry. 149:1992;1592-1594.
16. 19F magnetic resonance spectroscopy investigation in vivo of acute and steady state brain fluvoxamine levels in obsessive-compulsive disorder. Am J Psychiatry. 154(4):1997;516-522.
17. 19F magnetic resonance spectroscopy. Am J Psychiatry. 155(3):1998;380-384.
18. Weiss G., Ferretti J. Accuracy and precision in the estimation of peak areas and NOE factors. J Magn Res. 55:1983;397-407.
19. Wilde M.I., Plosker G.L., Benfield P. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness. Drugs. 46(5):1993;895-924.